Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Vesta Healthcare | 2024 | Debt Financing | $10.0M | New York |
| Day One Biopharmaceuticals | 2024 | Post Ipo Equity | $175.0M | South San Francisco |
| Magenta Medical | 2024 | Series Unknown | $105.0M | Kadima |
| LENZ Therapeutics | 2024 | Post Ipo Equity | $30.0M | Del Mar |
| AM Batteries | 2024 | Grant | $2.2M | Chelmsford |
| Frontier Medicines | 2024 | Series C | $20.0M | San Francisco |
| Bright Peak Therapeutics | 2024 | Series C | $90.0M | Allschwil |
| Ajax Therapeutics | 2024 | Series C | $95.0M | Cambridge |
| Bluejay Therapeutics | 2024 | Series C | $182.0M | San Mateo |
| Obsidian Therapeutics | 2024 | Series C | $160.5M | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 276 | Vesta Healthcare | Debt Financing | $10.0M | New York, United States |
| 277 | Day One Biopharmaceuticals | Post Ipo Equity | $175.0M | South San Francisco, United States |
| 278 | Magenta Medical | Series Unknown | $105.0M | Kadima, Israel |
| 279 | LENZ Therapeutics | Post Ipo Equity | $30.0M | Del Mar, United States |
| 280 | AM Batteries | Grant | $2.2M | Chelmsford, United States |
| 281 | Frontier Medicines | Series C | $20.0M | San Francisco, United States |
| 282 | Bright Peak Therapeutics | Series C | $90.0M | Allschwil, Switzerland |
| 283 | Ajax Therapeutics | Series C | $95.0M | Cambridge, United States |
| 284 | Bluejay Therapeutics | Series C | $182.0M | San Mateo, United States |
| 285 | Obsidian Therapeutics | Series C | $160.5M | Cambridge, United States |
Vesta Healthcare is a technology and clinical services organization that offers virtual care services.
Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Magenta Medical is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.
AM Batteries manufactures Li-ion batteries using solvent-free electrode manufacturing technology.
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
CervoMed a clinical-stage firm focused on discovering therapies for brain degenerative illnesses.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals.
MMI is focused on advancing robotic technology for soft tissue open surgery with the world's smallest wristed instruments.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Forward Therapeutics is a biopharma comapny targeting treatment of chronic inflammatory disorders.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.
RA Capital Management has invested in 369 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 24 different industry categories.
Among tracked funding rounds, Aiolos Bio received $245.0M in a Series A round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 369 companies.
Recent RA Capital Management portfolio additions include Vesta Healthcare, Day One Biopharmaceuticals, Magenta Medical, LENZ Therapeutics, AM Batteries. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors